Program
emicizumab
Its studies are mostly in Hemophilia A, led by 2 companies.
Furthest: phase 4, since Nov 20, 201713 company-led studies, 4 open or runningNext primary completion: Nov 19, 2026 (phase 4)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 123 open or running | phase 4since Nov 20, 2017 | Dec 2, 2015 | Nov 19, 2026phase 4 · NCT05181618 |
| Sanofi | 11 open or running | phase 4since Nov 17, 2023 | Nov 17, 2023 | May 28, 2028phase 4 · NCT06145373 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 2, 2015First study: phase 3 study in Hemophilia ANew to Hoffmann-La RocheHoffmann-La Roche · NCT02622321 · 113 enrolled · United States, Australia, Costa Rica and more
- Jun 7, 2016Phase 3 study in Hemophilia AHoffmann-La Roche · NCT02795767 · 88 enrolled · United States, Costa Rica, France and more
- Jul 26, 2016Phase 3 study in Hemophilia AHoffmann-La Roche · NCT02847637 · 152 enrolled · United States, Australia, Costa Rica and more
- Dec 21, 2016Phase 3 study in Hemophilia AHoffmann-La Roche · NCT03020160 · 48 enrolled · United States, Australia, Belgium and more
- Jun 15, 2017Phase 3 study in Hemophilia AHoffmann-La Roche · NCT03191799 · 195 enrolled · Australia, Belgium, Brazil and more
- Oct 17, 2017Phase 3 study in Hemophilia AHoffmann-La Roche · NCT03315455 · 85 enrolled · China, Hong Kong, Malaysia and more
- Nov 20, 2017Phase 4 study in Hemophilia AHoffmann-La Roche · NCT03361137 · 14 enrolled · United States
- Dec 13, 2017Phase 1 study in Hemophilia AHoffmann-La Roche · NCT03380780 · 16 enrolled · China
- Nov 7, 2019Phase 3 study in Hemophilia AHoffmann-La Roche · NCT04158648 · 73 enrolled · United States, Belgium, Canada and more
- Jun 11, 2020Phase 3 study in Hemophilia AHoffmann-La Roche · NCT04431726 · 55 enrolled · United States, Australia, Austria and more
- Dec 6, 2021Phase 4 study in Hemophilia AHoffmann-La Roche · NCT05181618 · 136 enrolled · United States, Brazil, Canada and more
- Nov 17, 2023Sanofi's first study: phase 4 study in Hemophilia ANew to SanofiSanofi · NCT06145373 · 20 planned · United States, Taiwan
- May 22, 2025Phase 3 study in von Willebrand Disease, Type 3Hoffmann-La Roche · NCT06998524 · 75 planned · United States, Belgium, Canada and more
- Nov 16, 2026Primary completion moved from 2027-04-30 to 2027-10-06Date moved laterphase 3 · +5 months · NCT06998524
Ahead
- Nov 19, 2026Primary completion: phase 4 study in Hemophilia AHoffmann-La Roche · NCT05181618
- Oct 6, 2027Primary completion: phase 3 study in von Willebrand Disease, Type 3Hoffmann-La Roche · NCT06998524
- May 28, 2028Primary completion: phase 4 study in Hemophilia ASanofi · NCT06145373
TargetBeta
“Coagulation factor IX and X other”ChEMBL 37, by rule
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06998524von Willebrand Disease, Type 3 · United States, Belgium, Canada and more | 3 | Recruiting | Hoffmann-La Roche | Oct 6, 2027 | 75 |
| NCT06145373Hemophilia A · United States, Taiwan | 4 | Recruiting | Sanofi | May 28, 2028 | 20 |
| NCT05181618Hemophilia A · United States, Brazil, Canada and more | 4 | Active, not recruiting | Hoffmann-La Roche | Nov 19, 2026 | 136 |
| NCT04431726Hemophilia A · United States, Australia, Austria and more | 3 | Active, not recruiting | Hoffmann-La Roche | May 22, 2023 | 55 |
| NCT04158648Hemophilia A · United States, Belgium, Canada and more | 3 | Completed | Hoffmann-La Roche | Oct 30, 2021 | 73 |
| NCT03380780Hemophilia A · China | 1 | Completed | Hoffmann-La Roche | Sep 18, 2018 | 16 |
| NCT03361137Hemophilia A · United States | 4 | Terminated | Hoffmann-La Roche | Mar 13, 2020 | 14 |
| NCT03315455Hemophilia A · China, Hong Kong, Malaysia and more | 3 | Completed | Hoffmann-La Roche | Aug 3, 2022 | 85 |
| NCT03191799Hemophilia A · Australia, Belgium, Brazil and more | 3 | Completed | Hoffmann-La Roche | Nov 19, 2020 | 195 |
| NCT03020160Hemophilia A · United States, Australia, Belgium and more | 3 | Completed | Hoffmann-La Roche | Dec 15, 2017 | 48 |
| NCT02847637Hemophilia A · United States, Australia, Costa Rica and more | 3 | Completed | Hoffmann-La Roche | Sep 15, 2017 | 152 |
| NCT02795767Hemophilia A · United States, Costa Rica, France and more | 3 | Completed | Hoffmann-La Roche | Apr 30, 2018 | 88 |
| NCT02622321Hemophilia A · United States, Australia, Costa Rica and more | 3 | Completed | Hoffmann-La Roche | Oct 25, 2016 | 113 |
How it is read
Names in the registry
- “Emicizumab”, 13 entries
Conditions, from the studies’ own filings
- Hemophilia A, 12 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.